Nathalie Schicktanz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathalie Schicktanz has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Dominique J. -F. de Quervain
Division of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland
16 shared publications Andreas Papassotiropoulos
13 shared publications- Dorothée Bentz
University of Basel
12 shared publications - Anja Zimmer
University of Basel
10 shared publications Thomas Schlitt
10 shared publicationsChristiane Gerhards
Division of Cognitive Neuroscience, Department of Biomedicine, University of Basel, Basel, Switzerland
8 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Center for Open Science in PsyArXiv
Continuous theta burst stimulation over bilateral occipitotemporal cortex does not modulate negative affective appraisal or memory: a randomised crossover trial
The bilateral occipitotemporal cortex (OTC) has been implicated in the successful encoding of aversive stimuli in fMRI studies, but its causal contribution to affective appraisal and memory formation has not been tested. We conducted a single-blind, active-control, counterbalanced crossover trial in which 27 healthy adults received bilateral 30 Hz continuous theta burst stimulation (cTBS) over the OTC or over an active control site, in two visits 7–21 days apart. Following stimulation, participants viewed 72 standardised emotional pictures (positive, neutral and negative), rated them for valence and arousal, performed a free-recall task, and re-rated the same pictures approximately 30 minutes later.The pre-registered primary outcome, valence ratings of negative pictures immediately after stimulation, did not differ between conditions (R = 0.01; mixed-model t (23.69) = 0.53, p = 0.60). Secondary analyses showed no effect of stimulation on immediate arousal ratings of negative pictures (R = < 0.01, p = 0.86), free-recall memory for negative pictures (R = 0.01, p = 0.80), or on any corresponding outcome for neutral or positive pictures. Among the secondary outcomes, delayed valence ratings of negative pictures differed nominally between conditions, but this effect did not survive correction for multiple comparisons.We found no evidence that the present bilateral 30 Hz cTBS protocol over group-defined OTC targets modulates immediate valence appraisal, arousal or subsequent memory for negative pictures.
- 12 June 2026
- Published by Center for Open Science in PsyArXiv
Open AccessContinuous theta burst stimulation over bilateral occipitotemporal cortex does not modulate negative affective appraisal or memory: a randomised crossover trial
The bilateral occipitotemporal cortex (OTC) has been implicated in the successful encoding of aversive stimuli in fMRI studies, but its causal contribution to affective appraisal and memory formation has not been tested. We conducted a single-blind, active-control, counterbalanced crossover trial in which 27 healthy adults received bilateral 30 Hz continuous theta burst stimulation (cTBS) over the OTC or over an active control site, in two visits 7–21 days apart. Following stimulation, participants viewed 72 standardised emotional pictures (positive, neutral and negative), rated them for valence and arousal, performed a free-recall task, and re-rated the same pictures approximately 30 minutes later.The pre-registered primary outcome, valence ratings of negative pictures immediately after stimulation, did not differ between conditions (R = 0.01; mixed-model t (23.69) = 0.53, p = 0.60). Secondary analyses showed no effect of stimulation on immediate arousal ratings of negative pictures (R = < 0.01, p = 0.86), free-recall memory for negative pictures (R = 0.01, p = 0.80), or on any corresponding outcome for neutral or positive pictures. Among the secondary outcomes, delayed valence ratings of negative pictures differed nominally between conditions, but this effect did not survive correction for multiple comparisons.We found no evidence that the present bilateral 30 Hz cTBS protocol over group-defined OTC targets modulates immediate valence appraisal, arousal or subsequent memory for negative pictures.
- Open Access
- 22 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e83850
A Compassion-Focused Online Single-Session Intervention to Reduce Academic Stress in University Students: Protocol for a Randomized Controlled Trial
Background: Among university students, the experience of academic stress is associated with symptoms of anxiety and depression. Single-session interventions (SSIs) are structured and accessible self-guided interventions, often delivered digitally, that integrate elements of empirically supported treatments. Compassion-Focused Therapy (CFT) has been shown to be beneficial in alleviating stress, anxiety, and depression. However, the effectiveness of CFT (1) in the academic context, and (2) when delivered in brief digital formats, has not yet been tested. Objective: This study aims to evaluate the effectiveness of a compassion-focused online SSI for reducing stress among university students. Methods: University students aged 18‐65 years that indicate at least mild stress (a score >7 on the stress scale of the Depression Anxiety Stress Scale–21 [DASS-21]) will be recruited from German-speaking Switzerland. The target sample size is 156 participants randomly assigned to either the intervention or the waitlist control group. The 45-minute intervention follows the typical SSI structure and combines psychoeducation on academic stress, core CFT principles, guided breathing, compassion imagery exercises, and includes an action plan. Assessments will be conducted at baseline, 24 hours after the intervention, and at the 1-week follow-up. The primary outcome is the change in stress between baseline and 1-week follow-up, measured with the stress scale of the DASS-21. Secondary outcomes include depressive symptoms and anxiety measured with the depression and anxiety scales of the DASS-21 between baseline and 1-week follow-up. Data will be analyzed using linear (mixed-effects) models. Results: Ethical approval for the study was received in September 2025. Recruitment and data collection started in November 2025; data collection will conclude once 172 participants have been enrolled. As of April 15, 2026, 67 participants have been enrolled. Data analysis is planned for winter 2026, with the primary findings being prepared for publication in the spring of 2027. Conclusions: To our knowledge, this study is the first randomized controlled trial to examine the effects of a compassion-focused online SSI on reducing stress in university students. If the program proves to be effective, it would offer a low-threshold, cost-effective, and scalable mental health intervention for the academic context.
- 22 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e83850
Open AccessA Compassion-Focused Online Single-Session Intervention to Reduce Academic Stress in University Students: Protocol for a Randomized Controlled Trial
Background: Among university students, the experience of academic stress is associated with symptoms of anxiety and depression. Single-session interventions (SSIs) are structured and accessible self-guided interventions, often delivered digitally, that integrate elements of empirically supported treatments. Compassion-Focused Therapy (CFT) has been shown to be beneficial in alleviating stress, anxiety, and depression. However, the effectiveness of CFT (1) in the academic context, and (2) when delivered in brief digital formats, has not yet been tested. Objective: This study aims to evaluate the effectiveness of a compassion-focused online SSI for reducing stress among university students. Methods: University students aged 18‐65 years that indicate at least mild stress (a score >7 on the stress scale of the Depression Anxiety Stress Scale–21 [DASS-21]) will be recruited from German-speaking Switzerland. The target sample size is 156 participants randomly assigned to either the intervention or the waitlist control group. The 45-minute intervention follows the typical SSI structure and combines psychoeducation on academic stress, core CFT principles, guided breathing, compassion imagery exercises, and includes an action plan. Assessments will be conducted at baseline, 24 hours after the intervention, and at the 1-week follow-up. The primary outcome is the change in stress between baseline and 1-week follow-up, measured with the stress scale of the DASS-21. Secondary outcomes include depressive symptoms and anxiety measured with the depression and anxiety scales of the DASS-21 between baseline and 1-week follow-up. Data will be analyzed using linear (mixed-effects) models. Results: Ethical approval for the study was received in September 2025. Recruitment and data collection started in November 2025; data collection will conclude once 172 participants have been enrolled. As of April 15, 2026, 67 participants have been enrolled. Data analysis is planned for winter 2026, with the primary findings being prepared for publication in the spring of 2027. Conclusions: To our knowledge, this study is the first randomized controlled trial to examine the effects of a compassion-focused online SSI on reducing stress in university students. If the program proves to be effective, it would offer a low-threshold, cost-effective, and scalable mental health intervention for the academic context.
- Open Access
- 18 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Plasma sodium levels are related to resting motor threshold in healthy humans
Electrolyte homeostasis is essential for normal neuronal function and clinically relevant imbalances can provoke neurological symptoms, including seizures. However, whether electrolyte variations within the normal physiological range affect cortical excitability remains unclear. In this exploratory secondary analysis, we examined baseline data from 42 healthy participants enrolled in a previously conducted clinical trial. We found a significant correlation between plasma sodium levels within the normal physiological range (136–143 mmol/L) and resting motor threshold ( r = 0.47, p = 0.002), an indirect index of cortical excitability, suggesting that lower sodium concentrations may be associated with increased cortical excitability. No significant associations were observed for chloride, potassium, phosphate, or calcium. These preliminary findings raise the possibility that subtle interindividual differences in plasma sodium levels are related to variability in corticospinal excitability. Given that this was a non-prespecified, secondary analysis, further controlled studies are warranted to confirm the association and investigate the underlying mechanisms.
- 18 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Open AccessPlasma sodium levels are related to resting motor threshold in healthy humans
Electrolyte homeostasis is essential for normal neuronal function and clinically relevant imbalances can provoke neurological symptoms, including seizures. However, whether electrolyte variations within the normal physiological range affect cortical excitability remains unclear. In this exploratory secondary analysis, we examined baseline data from 42 healthy participants enrolled in a previously conducted clinical trial. We found a significant correlation between plasma sodium levels within the normal physiological range (136–143 mmol/L) and resting motor threshold ( r = 0.47, p = 0.002), an indirect index of cortical excitability, suggesting that lower sodium concentrations may be associated with increased cortical excitability. No significant associations were observed for chloride, potassium, phosphate, or calcium. These preliminary findings raise the possibility that subtle interindividual differences in plasma sodium levels are related to variability in corticospinal excitability. Given that this was a non-prespecified, secondary analysis, further controlled studies are warranted to confirm the association and investigate the underlying mechanisms.
- Open Access
- 25 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
A Compassion-Focused Online Single-Session Intervention to reduce academic stress: Protocol for a randomized-controlled trial (Preprint)
BACKGROUND Among university students, the experience of academic stress is associated with symptoms of anxiety and depression. Single-session interventions (SSI) are structured and accessible self-guided interventions, often delivered digitally, that integrate elements of empirically supported treatments. Compassion-Focused Therapy (CFT) has been shown to be beneficial to alleviate stress, anxiety and depression. However, the effectiveness of CFT (1) in the academic context, and (2) when delivered in brief digital formats has not yet been tested. OBJECTIVE This randomized controlled trial aims to evaluate the effectiveness of a compassion-focused online single-session intervention (SSI) for reducing stress among university students. METHODS University students aged 18–65 years that indicate at least mild stress (a score >7 on the stress scale of the Depression Anxiety Stress Scales–21/DASS-21) will be recruited from German-speaking Switzerland. The target sample size are 156 participants randomly assigned to either the intervention or the waitlist control group. The 45-minute intervention follows the typical SSI structure, and combines psychoeducation on academic stress, core CFT principles with guided breathing and compassion imagery exercises, and includes an action plan. Assessments will be conducted at baseline, 24 hours after the intervention, and at the one-week follow-up. The primary outcome is the change in stress between baseline and one-week follow-up, measured with the stress scale of the DASS-21. Secondary outcomes include depressive symptoms, and anxiety measured with DASS-21 depression and anxiety scales between baseline and one-week follow-up. Data will be analyzed using linear (mixed-effects) models. RESULTS Ethical approval for the study was received in September 2025. Recruitment is scheduled to begin in November 2025, and data collection will conclude once 172 participants have been enrolled and completed their participation. Data analysis is planned for spring 2026, with the primary findings being prepared for publication in summer of 2026. CONCLUSIONS To our knowledge, the current study is the first randomized-controlled trial to examine the effects of a compassion-focused online single-session intervention on reducing stress in university students. If the program proofs to be effective, it would offer a low-threshold, cost-effective, and scalable mental health intervention for the academic context. CLINICALTRIAL DRKS-ID DRKS00038409
- 25 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Compassion-Focused Online Single-Session Intervention to reduce academic stress: Protocol for a randomized-controlled trial (Preprint)
BACKGROUND Among university students, the experience of academic stress is associated with symptoms of anxiety and depression. Single-session interventions (SSI) are structured and accessible self-guided interventions, often delivered digitally, that integrate elements of empirically supported treatments. Compassion-Focused Therapy (CFT) has been shown to be beneficial to alleviate stress, anxiety and depression. However, the effectiveness of CFT (1) in the academic context, and (2) when delivered in brief digital formats has not yet been tested. OBJECTIVE This randomized controlled trial aims to evaluate the effectiveness of a compassion-focused online single-session intervention (SSI) for reducing stress among university students. METHODS University students aged 18–65 years that indicate at least mild stress (a score >7 on the stress scale of the Depression Anxiety Stress Scales–21/DASS-21) will be recruited from German-speaking Switzerland. The target sample size are 156 participants randomly assigned to either the intervention or the waitlist control group. The 45-minute intervention follows the typical SSI structure, and combines psychoeducation on academic stress, core CFT principles with guided breathing and compassion imagery exercises, and includes an action plan. Assessments will be conducted at baseline, 24 hours after the intervention, and at the one-week follow-up. The primary outcome is the change in stress between baseline and one-week follow-up, measured with the stress scale of the DASS-21. Secondary outcomes include depressive symptoms, and anxiety measured with DASS-21 depression and anxiety scales between baseline and one-week follow-up. Data will be analyzed using linear (mixed-effects) models. RESULTS Ethical approval for the study was received in September 2025. Recruitment is scheduled to begin in November 2025, and data collection will conclude once 172 participants have been enrolled and completed their participation. Data analysis is planned for spring 2026, with the primary findings being prepared for publication in summer of 2026. CONCLUSIONS To our knowledge, the current study is the first randomized-controlled trial to examine the effects of a compassion-focused online single-session intervention on reducing stress in university students. If the program proofs to be effective, it would offer a low-threshold, cost-effective, and scalable mental health intervention for the academic context. CLINICALTRIAL DRKS-ID DRKS00038409
- Open Access
- 12 September 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e266
Effects of the histone deacetylase inhibitor valproic acid in combination with fear-memory retrieval before exposure therapy for spider phobia: A randomized controlled trial
Background: Return of fear after successful exposure therapy for a phobia is a common clinical challenge. A previous study on mice demonstrated that the persistent attenuation of remote fear memories can be achieved by combining histone deacetylase inhibitors (HDACis) with fear-memory retrieval prior to extinction training. Methods: To evaluate the translational potential of this approach, we conducted a randomized, double-blind, placebo-controlled trial. Forty-eight individuals with DSM-IV spider phobia received either HDACi valproic acid (VPA, 500 mg) or a placebo prior to the retrieval of fear memory, followed by exposure therapy in virtual reality. Results: No significant group difference was found in terms of behavioral change on the behavioral approach test at 3 months follow-up and baseline (primary outcome). However, the VPA group displayed significantly reduced fear in two self-report questionnaires related to spider phobia (Fear of Spiders Questionnaire; Spider Phobia Beliefs Questionnaire) as compared to the placebo group. No group differences were observed for psychophysiological indicators of fear. Conclusions: The favorable impact of a single administration of VPA in combination with fear-memory retrieval prior to exposure therapy suggests that it might be an effective way to enhance symptom improvement at the subjective level in the treatment of phobias. Further studies need to investigate the conditions under which an improvement on the psychophysiological and behavioral levels can be achieved as well.
- 12 September 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e266
Open AccessEffects of the histone deacetylase inhibitor valproic acid in combination with fear-memory retrieval before exposure therapy for spider phobia: A randomized controlled trial
Background: Return of fear after successful exposure therapy for a phobia is a common clinical challenge. A previous study on mice demonstrated that the persistent attenuation of remote fear memories can be achieved by combining histone deacetylase inhibitors (HDACis) with fear-memory retrieval prior to extinction training. Methods: To evaluate the translational potential of this approach, we conducted a randomized, double-blind, placebo-controlled trial. Forty-eight individuals with DSM-IV spider phobia received either HDACi valproic acid (VPA, 500 mg) or a placebo prior to the retrieval of fear memory, followed by exposure therapy in virtual reality. Results: No significant group difference was found in terms of behavioral change on the behavioral approach test at 3 months follow-up and baseline (primary outcome). However, the VPA group displayed significantly reduced fear in two self-report questionnaires related to spider phobia (Fear of Spiders Questionnaire; Spider Phobia Beliefs Questionnaire) as compared to the placebo group. No group differences were observed for psychophysiological indicators of fear. Conclusions: The favorable impact of a single administration of VPA in combination with fear-memory retrieval prior to exposure therapy suggests that it might be an effective way to enhance symptom improvement at the subjective level in the treatment of phobias. Further studies need to investigate the conditions under which an improvement on the psychophysiological and behavioral levels can be achieved as well.
- Open Access
- 4 June 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (6) , e70600
Effects of a Valerian‐Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial
Objective/Background: This study evaluated the feasibility of investigating the effect of a valerian and hops‐based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.Methods: A randomized, double‐blind, placebo‐controlled study was conducted in 40 participants over a 21‐day run‐in period and a 21‐day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).Results: The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, p = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well‐tolerated.Conclusions: The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.Trial Registration: The trial has been preregistered at www.clinicaltrials.gov (NCT05684523).
- 4 June 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (6) , e70600
Open AccessEffects of a Valerian‐Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial
Objective/Background: This study evaluated the feasibility of investigating the effect of a valerian and hops‐based herbal medication (Ze 91019) on daytime cognitive performance, psychological parameters, and sleep measures in individuals with occasional sleep problems.Methods: A randomized, double‐blind, placebo‐controlled study was conducted in 40 participants over a 21‐day run‐in period and a 21‐day treatment period. Participants used Fitbit sleep trackers and completed daily online cognitive tests (i.e., reaction time and working memory), and surveys to assess subjective psychological outcomes (i.e., cognitive performance, stress levels, tiredness, mood, quality of life, and motivation).Results: The study design proved feasible, with high adherence to the study protocol. Exploratory analyses revealed a statistically significant increase in sleep duration during the treatment period for participants using Ze 91019 compared to placebo (mean daily increase: 21.7 min, p = 0.019) without statistically significant effects on cognitive or psychological outcomes. Moreover, Ze 91019 statistically significantly increased the sleep duration of the shortest night in the treatment period by 48.7 minutes. The medication was well‐tolerated.Conclusions: The study design proved feasible, and Ze 91019 increased sleep duration without affecting daytime cognitive or psychological outcomes.Trial Registration: The trial has been preregistered at www.clinicaltrials.gov (NCT05684523).
- Open Access
Effects of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Fear Memory Retrieval before Exposure Therapy for Spider Phobia: A Randomized Controlled Trial
Return of fear after successful exposure therapy for phobia is a common clinical challenge. A previous study on mice demonstrated that the persistent attenuation of remote fear memories can be achieved by combining histone deacetylase inhibitors (HDACis) with fear-memory retrieval prior to extinction training. To evaluate the translational potential of this approach, we conducted a randomized, double-blind placebo-controlled trial. Forty-eight individuals with DSM-IV spider phobia received either HDACi valproic acid (VPA, 500 mg) or a placebo prior to the retrieval of fear memory followed by exposure therapy in virtual reality. No significant group difference was found in terms of behavioral change on the behavioral approach test at 3 months follow-up and baseline (primary outcome). However, the VPA group displayed significantly reduced fear in two self-report questionnaires related to spider phobia (Fear of Spider Questionnaire; Spider Phobia Beliefs Questionnaire) as compared to the placebo group. No group differences were observed for psychophysiological indicators of fear. The favorable impact of a single administration of VPA in combination with fear-memory retrieval prior to exposure therapy suggests that it might be an effective way to enhance symptom improvement at the subjective level in the treatment of phobias. Further studies need to investigate the conditions under which an improvement on the physiological and behavioral levels can be achieved as well.
Open AccessEffects of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Fear Memory Retrieval before Exposure Therapy for Spider Phobia: A Randomized Controlled Trial
Return of fear after successful exposure therapy for phobia is a common clinical challenge. A previous study on mice demonstrated that the persistent attenuation of remote fear memories can be achieved by combining histone deacetylase inhibitors (HDACis) with fear-memory retrieval prior to extinction training. To evaluate the translational potential of this approach, we conducted a randomized, double-blind placebo-controlled trial. Forty-eight individuals with DSM-IV spider phobia received either HDACi valproic acid (VPA, 500 mg) or a placebo prior to the retrieval of fear memory followed by exposure therapy in virtual reality. No significant group difference was found in terms of behavioral change on the behavioral approach test at 3 months follow-up and baseline (primary outcome). However, the VPA group displayed significantly reduced fear in two self-report questionnaires related to spider phobia (Fear of Spider Questionnaire; Spider Phobia Beliefs Questionnaire) as compared to the placebo group. No group differences were observed for psychophysiological indicators of fear. The favorable impact of a single administration of VPA in combination with fear-memory retrieval prior to exposure therapy suggests that it might be an effective way to enhance symptom improvement at the subjective level in the treatment of phobias. Further studies need to investigate the conditions under which an improvement on the physiological and behavioral levels can be achieved as well.
- Open Access
- 8 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 2085-2094
The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach
Working memory (WM), a key component of cognitive functions, is often impaired in psychiatric disorders such as schizophrenia. Through a genome-guided drug repurposing approach, we identified fampridine, a potassium channel blocker used to improve walking in multiple sclerosis, as a candidate for modulating WM. In a subsequent double-blind, randomized, placebo-controlled, crossover trial in 43 healthy young adults (ClinicalTrials.gov, NCT04652557), we assessed fampridine’s impact on WM (3-back d-prime, primary outcome) after 3.5 days of repeated administration (10 mg twice daily). Independently of baseline cognitive performance, no significant main effect was observed (Wilcoxon P = 0.87, r = 0.026). However, lower baseline performance was associated with higher working memory performance after repeated intake of fampridine compared to placebo (rs = −0.37, P = 0.014, n = 43). Additionally, repeated intake of fampridine lowered resting motor threshold (F(1,37) = 5.31, P = 0.027, R2β = 0.01), the non-behavioral secondary outcome, indicating increased cortical excitability linked to cognitive function. Fampridine’s capacity to enhance WM in low-performing individuals and to increase brain excitability points to its potential value for treating WM deficits.
- 8 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (5) , 2085-2094
Open AccessThe effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach
Working memory (WM), a key component of cognitive functions, is often impaired in psychiatric disorders such as schizophrenia. Through a genome-guided drug repurposing approach, we identified fampridine, a potassium channel blocker used to improve walking in multiple sclerosis, as a candidate for modulating WM. In a subsequent double-blind, randomized, placebo-controlled, crossover trial in 43 healthy young adults (ClinicalTrials.gov, NCT04652557), we assessed fampridine’s impact on WM (3-back d-prime, primary outcome) after 3.5 days of repeated administration (10 mg twice daily). Independently of baseline cognitive performance, no significant main effect was observed (Wilcoxon P = 0.87, r = 0.026). However, lower baseline performance was associated with higher working memory performance after repeated intake of fampridine compared to placebo (rs = −0.37, P = 0.014, n = 43). Additionally, repeated intake of fampridine lowered resting motor threshold (F(1,37) = 5.31, P = 0.027, R2β = 0.01), the non-behavioral secondary outcome, indicating increased cortical excitability linked to cognitive function. Fampridine’s capacity to enhance WM in low-performing individuals and to increase brain excitability points to its potential value for treating WM deficits.
- Open Access
- 1 April 2024
- Published by MDPI AG in Methods and Protocols
- Vol. 7 (2) , 31
Assessing Stress Induced by Fluid Shifts and Reduced Cerebral Clearance during Robotic-Assisted Laparoscopic Radical Prostatectomy under Trendelenburg Positioning (UroTreND Study)
In addition to general anesthesia and mechanical ventilation, robotic-assisted laparoscopic radical prostatectomy (RALP) necessitates maintaining a capnoperitoneum and placing the patient in a pronounced downward tilt (Trendelenburg position). While the effects of the resulting fluid shift on the cardiovascular system seem to be modest and well tolerated, the effects on the brain and the blood–brain barrier have not been thoroughly investigated. Previous studies indicated that select patients showed an increase in the optic nerve sheath diameter (ONSD), detected by ultrasound during RALP, which suggests an elevation in intracranial pressure. We hypothesize that the intraoperative fluid shift results in endothelial dysfunction and reduced cerebral clearance, potentially leading to transient neuronal damage. This prospective, monocentric, non-randomized, controlled clinical trial will compare RALP to conventional open radical prostatectomy (control group) in a total of 50 subjects. The primary endpoint will be the perioperative concentration of neurofilament light chain (NfL) in blood using single-molecule array (SiMoA) as a measure for neuronal damage. As secondary endpoints, various other markers for endothelial function, inflammation, and neuronal damage as well as the ONSD will be assessed. Perioperative stress will be evaluated by questionnaires and stress hormone levels in saliva samples. Furthermore, the subjects will participate in functional tests to evaluate neurocognitive function. Each subject will be followed up until discharge. Conclusion: This trial aims to expand current knowledge as well as to develop strategies for improved monitoring and higher safety of patients undergoing RALP. The trial was registered with the German Clinical Trials Register DRKS00031041 on 11 January 2023.
- 1 April 2024
- Published by MDPI AG in Methods and Protocols
- Vol. 7 (2) , 31
Open AccessAssessing Stress Induced by Fluid Shifts and Reduced Cerebral Clearance during Robotic-Assisted Laparoscopic Radical Prostatectomy under Trendelenburg Positioning (UroTreND Study)
In addition to general anesthesia and mechanical ventilation, robotic-assisted laparoscopic radical prostatectomy (RALP) necessitates maintaining a capnoperitoneum and placing the patient in a pronounced downward tilt (Trendelenburg position). While the effects of the resulting fluid shift on the cardiovascular system seem to be modest and well tolerated, the effects on the brain and the blood–brain barrier have not been thoroughly investigated. Previous studies indicated that select patients showed an increase in the optic nerve sheath diameter (ONSD), detected by ultrasound during RALP, which suggests an elevation in intracranial pressure. We hypothesize that the intraoperative fluid shift results in endothelial dysfunction and reduced cerebral clearance, potentially leading to transient neuronal damage. This prospective, monocentric, non-randomized, controlled clinical trial will compare RALP to conventional open radical prostatectomy (control group) in a total of 50 subjects. The primary endpoint will be the perioperative concentration of neurofilament light chain (NfL) in blood using single-molecule array (SiMoA) as a measure for neuronal damage. As secondary endpoints, various other markers for endothelial function, inflammation, and neuronal damage as well as the ONSD will be assessed. Perioperative stress will be evaluated by questionnaires and stress hormone levels in saliva samples. Furthermore, the subjects will participate in functional tests to evaluate neurocognitive function. Each subject will be followed up until discharge. Conclusion: This trial aims to expand current knowledge as well as to develop strategies for improved monitoring and higher safety of patients undergoing RALP. The trial was registered with the German Clinical Trials Register DRKS00031041 on 11 January 2023.
- Open Access
- 3 October 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (41)
Human cerebellum and corticocerebellar connections involved in emotional memory enhancement
Emotional information is better remembered than neutral information. Extensive evidence indicates that the amygdala and its interactions with other cerebral regions play an important role in the memory-enhancing effect of emotional arousal. While the cerebellum has been found to be involved in fear conditioning, its role in emotional enhancement of episodic memory is less clear. To address this issue, we used a whole-brain functional MRI approach in 1,418 healthy participants. First, we identified clusters significantly activated during enhanced memory encoding of negative and positive emotional pictures. In addition to the well-known emotional memory–related cerebral regions, we identified a cluster in the cerebellum. We then used dynamic causal modeling and identified several cerebellar connections with increased connection strength corresponding to enhanced emotional memory, including one to a cluster covering the amygdala and hippocampus, and bidirectional connections with a cluster covering the anterior cingulate cortex. The present findings indicate that the cerebellum is an integral part of a network involved in emotional enhancement of episodic memory.
- 3 October 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (41)
Open AccessHuman cerebellum and corticocerebellar connections involved in emotional memory enhancement
Emotional information is better remembered than neutral information. Extensive evidence indicates that the amygdala and its interactions with other cerebral regions play an important role in the memory-enhancing effect of emotional arousal. While the cerebellum has been found to be involved in fear conditioning, its role in emotional enhancement of episodic memory is less clear. To address this issue, we used a whole-brain functional MRI approach in 1,418 healthy participants. First, we identified clusters significantly activated during enhanced memory encoding of negative and positive emotional pictures. In addition to the well-known emotional memory–related cerebral regions, we identified a cluster in the cerebellum. We then used dynamic causal modeling and identified several cerebellar connections with increased connection strength corresponding to enhanced emotional memory, including one to a cluster covering the amygdala and hippocampus, and bidirectional connections with a cluster covering the anterior cingulate cortex. The present findings indicate that the cerebellum is an integral part of a network involved in emotional enhancement of episodic memory.